Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders

M. R. Liebowitz, E. Hollander, F. Schneier, R. Campeas, L. Welkowitz, J. Hatterer, B. Fallon

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive‐compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO‐A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalActa Psychiatrica Scandinavica
Issue number360 S
StatePublished - Sep 1990
Externally publishedYes


  • MAOI
  • OCD
  • PTSD
  • RIMA
  • atypical depression
  • bulimia
  • social phobia

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders'. Together they form a unique fingerprint.

Cite this